The increase in risk
The much larger control population did not develop malignant neoplasms at nearly the same rate as the cancer survivors. In fact, the rate of people without a history of cancer developing a malignant neoplasm was nearly one quarter the rate at which the hematological cancer survivors developed SMNs.
On average, nonsolid SMNs developed 5.9 years after the index date, which started two years after the last treatment. The average diagnosis for solid SMNs was 9.6 years, though risk increased dramatically after 15 years.